BTIG Research Increases Organogenesis (NASDAQ:ORGO) Price Target to $9.00

Organogenesis (NASDAQ:ORGO) had its price objective increased by stock analysts at BTIG Research from $7.00 to $9.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price target indicates a potential upside of 75.44% from the company’s previous close.

ORGO has been the topic of several other reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Organogenesis in a report on Thursday, November 13th. Wall Street Zen upgraded Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Cantor Fitzgerald increased their target price on Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.00.

Organogenesis Stock Down 7.1%

Shares of NASDAQ ORGO opened at $5.13 on Thursday. Organogenesis has a 52-week low of $2.61 and a 52-week high of $7.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32. The business has a fifty day moving average of $4.61 and a two-hundred day moving average of $4.26. The stock has a market cap of $651.05 million, a PE ratio of -42.75 and a beta of 1.68.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.11. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. The business had revenue of $150.86 million for the quarter, compared to analyst estimates of $134.10 million. Organogenesis has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Institutional Trading of Organogenesis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORGO. Trexquant Investment LP acquired a new position in shares of Organogenesis in the 1st quarter valued at $516,000. Assenagon Asset Management S.A. increased its holdings in Organogenesis by 748.1% in the second quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company’s stock valued at $10,460,000 after purchasing an additional 2,520,941 shares during the last quarter. Cerity Partners LLC lifted its stake in Organogenesis by 48.2% in the first quarter. Cerity Partners LLC now owns 74,880 shares of the company’s stock valued at $323,000 after buying an additional 24,362 shares during the period. Vanguard Group Inc. boosted its holdings in Organogenesis by 23.4% during the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock worth $19,144,000 after buying an additional 841,618 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Organogenesis by 45.3% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 667,529 shares of the company’s stock worth $2,884,000 after buying an additional 208,038 shares during the period. 49.57% of the stock is currently owned by institutional investors and hedge funds.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.